Literature DB >> 26381432

The prevalence of mild cognitive impairment with type 2 diabetes mellitus among elderly people in China: A cross-sectional study.

Yuxia Gao1, Yanyu Xiao2, Rujuan Miao3, Jiangang Zhao4, Mingfei Cui4, Guowei Huang5, Ma Fei6.   

Abstract

BACKGROUND: In absence of curative treatments for dementia with type 2 diabetes mellitus (T2DM), mild cognitive impairment (MCI) in T2DM, the preclinical transitional states of dementia with T2DM has attracted dramatic attention. Our study was to estimate the prevalence and distribution of MCI in T2DM subjects from China, and identify influencing factors of subjects in MCI with T2DM.
METHODS: In the present study, we performed cluster random sampling of 8213 people aged 65 years and older in Tianjin, a metropolitan city, located in northern China. All participants were interviewed and screened for T2DM. 1109 subjects with T2DM were initially screened with American Diabetes Association criteria for diagnosis of diabetes mellitus and were diagnosed with MCI and dementia according to the criteria of DSM-IIIR. The prevalence of MCI and dementia in subjects with T2DM were compared with that in ordinary subjects. Logistic regression analyses were performed to evaluate risk of MCI with T2DM.
RESULTS: Among all 8213 subjects, overall MCI and dementia with T2DM prevalence were 13.5% and 2.34%, respectively. Compared with ordinary subjects, the prevalence of MCI in the present study was more frequent than the prevalence of MCI for the general population in almost each age group. In the univariate analyses, among all diabetic subjects, compared with cognitive intactly subjects, MCI subjects had significantly higher levels of age, current smoking, mean waist circumference, duration from onset of diabetes, insulin intake, systolic BP, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c) and immunoreactive insulin (IRI). In multivariate logistic regression analyses, variables including current smoking, duration from onset of diabetes, FPG, HbA1c and IRI were significantly associated with increased risk for MCI with T2DM, the ORs were 1.36,1.33,1.17,1.25 and 1.33, respectively (all P<0.05).
CONCLUSIONS: The present study confirms the high prevalence of MCI with T2DM among the elderly population of China. T2DM is related to a higher risk of MCI in a population with a high prevalence of this disorder and may aggravate the clinical picture as a concomitant factor.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cross-sectional study; Dementia; Mild cognitive impairment; Prevalence; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2015        PMID: 26381432     DOI: 10.1016/j.archger.2015.09.003

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  23 in total

Review 1.  The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis.

Authors:  Yue You; Zhizhen Liu; Yannan Chen; Ying Xu; Jiawei Qin; Shuai Guo; Jia Huang; Jing Tao
Journal:  Acta Diabetol       Date:  2021-01-08       Impact factor: 4.280

2.  The role of religious coping and social support on medication adherence and quality of life among the elderly with type 2 diabetes.

Authors:  Mohsen Saffari; Chung-Ying Lin; Hui Chen; Amir H Pakpour
Journal:  Qual Life Res       Date:  2019-04-29       Impact factor: 4.147

3.  Population-attributable fractions of risk factors for all-cause dementia in China rural and urban areas: a cross-sectional study.

Authors:  Fei-Fei Hu; Gui-Rong Cheng; Dan Liu; Qian Liu; Xu-Guang Gan; Lin Li; Xiao-Dan Wang; Bo Zhang; Li-Na An; Cong Chen; Ming-Jun Zou; Lang Xu; Yang-Ming Ou; Yu-Shan Chen; Jin-Quan Li; Zhen Wei; Yue-Yi Wang; Qiong Wu; Xing-Xing Chen; Xi-Fei Yang; Qing-Ming Wu; Lei Feng; Jing-Jing Zhang; Heng Xu; Ya-Fu Yu; Meng-Liu Yang; Jin Qian; Peng-Fei Lian; Li-Yan Fu; Ting-Ting Duan; Yuan Tian; Xi Cheng; Xin-Wen Li; Pin-Ting Yan; Guowei Huang; Hongxin Dong; Yong Ji; Yan Zeng
Journal:  J Neurol       Date:  2021-11-28       Impact factor: 4.849

4.  Equity in the Provision of Diabetes Self-Management Education and Support.

Authors:  Julia E Blanchette; Siobhan P Aaron; Nancy A Allen; Michelle L Litchman
Journal:  Diabetes Spectr       Date:  2022-08-15

5.  Relationships between cerebral structure and cognitive function in African Americans with type 2 diabetes.

Authors:  Timothy M Hughes; Kaycee M Sink; Jeff D Williamson; Christina E Hugenschmidt; Benjamin C Wagner; Christopher T Whitlow; Jianzhao Xu; S Carrie Smith; Lenore J Launer; Joshua I Barzilay; Faramarz Ismail-Beigi; R Nick Bryan; Fang-Chi Hsu; Donald W Bowden; Joseph A Maldjian; Jasmin Divers; Barry I Freedman
Journal:  J Diabetes Complications       Date:  2018-05-29       Impact factor: 2.852

6.  Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes.

Authors:  Michael Quartuccio; Brian Buta; Rita R Kalyani
Journal:  Curr Geriatr Rep       Date:  2017-07-28

7.  Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort.

Authors:  Wei Li; Shannon L Risacher; Edgar Huang; Andrew J Saykin
Journal:  Neurology       Date:  2016-07-06       Impact factor: 9.910

Review 8.  Mitochondrial Dysfunction and Mitophagy Closely Cooperate in Neurological Deficits Associated with Alzheimer's Disease and Type 2 Diabetes.

Authors:  Sangita Paul; Debarpita Saha; Binukumar Bk
Journal:  Mol Neurobiol       Date:  2021-04-01       Impact factor: 5.590

9.  Low uric acid is a risk factor in mild cognitive impairment.

Authors:  LingLing Xue; YongBing Liu; HuiPing Xue; Jin Xue; KaiXuan Sun; LinFeng Wu; Ping Hou
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-11       Impact factor: 2.570

10.  The Protective Effect of Astaxanthin on Cognitive Function via Inhibition of Oxidative Stress and Inflammation in the Brains of Chronic T2DM Rats.

Authors:  Yonghao Feng; Aiqun Chu; Qiong Luo; Men Wu; Xiaohong Shi; Yinghui Chen
Journal:  Front Pharmacol       Date:  2018-07-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.